Gamma Delta Therapeutics
GammaDelta Therapeutics was formed in 2016 by Abingworth with support from what is now Cancer Research Horizons. GammaDelta Therapeutics was founded on pioneering research funded in part by Cancer Research UK, led by Professor Adrian Hayday and Dr Oliver Nussbaumer at King’s College London and the Francis Crick Institute, into gamma delta (γδ) T cells. GammaDelta Therapeutics aims to harness the unique properties of γδ T cells to improve patient outcomes and survival rates among patients with haematological malignancies and solid tumours.